June 25, 2025 a 09:00 am
HOLX: Analysts Ratings - Hologic, Inc.
Hologic, Inc. has shown consistent strength in the diagnostics and medical imaging sectors. Recent analyst ratings suggest a stalwart position with a strong orientation towards holding shares, indicating market stability. With advanced products and a robust growth strategy, Hologic remains a significant player in women's health care solutions, keeping investor interest poised.
Historical Stock Grades
Analyzing the latest stock grades, Hologic's position in the market is largely seen as stable, with a predominance of 'Hold' recommendations, reflecting caution. The scorebar visualization provides insight into the distribution of ratings, highlighting the company's current standing.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 3 | |
| Hold | 14 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment around Hologic has shown a cautious stance with a growth in 'Hold' ratings over time, suggesting a conservative market outlook. Recent months have shown:
- An increase in 'Hold' recommendations from March to June 2025, indicating a more cautious approach.
- Consistency in 'Strong Buy' counts, showing some investor confidence in massive growth potential.
- A notable reduction from 'Strong Buy' and 'Buy' categories in late 2024, pointing towards market volatility.
Percentage Trends
Analyzing percentage trends reveals a discernible shift in analyst sentiment. Overall, the conservative stance is prominent:
- Reduction in 'Strong Buy' and 'Buy' ratings with a corresponding rise in 'Hold' percentages—highlighting market caution.
- In the last six months, 'Hold' ratings have surged from approximately 20% to 64%.
- 'Strong Sell' ratings have nearly vanished, showcasing a decrease in pessimistic views.
Latest Analyst Recommendations
Recent analyst actions have mainly maintained the current stance, with no significant shifts in direction. This stability suggests continued confidence in the midterm outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-28 | Hold | Hold | Needham |
| 2025-05-13 | Overweight | Overweight | Stephens & Co. |
| 2025-05-05 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-05-02 | Hold | Hold | Needham |
| 2025-05-02 | Outperform | Outperform | Raymond James |
Analyst Recommendations with Change of Opinion
Within the past quarters, there have been notable changes with some downgrades reflecting shifts in expectations.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-02-06 | Market Perform | Outperform | Leerink Partners |
| 2025-02-03 | Hold | Buy | Needham |
| 2024-10-01 | Neutral | Buy | Citigroup |
| 2024-04-03 | Buy | Neutral | Citigroup |
| 2023-07-14 | Buy | Hold | Needham |
Interpretation
Hologic’s analyst sentiment reflects a mixed but moderately optimistic view. There is a clear stability in recommendations, with the majority leaning towards a 'Hold'. The tangible hesitancy among analysts hints at caution due to market variables yet an absence of pessimistic sell signals indicates underlying confidence. As opinions remain largely unchanged, it suggests that market perceptions about Hologic are solidifying.
Conclusion
Hologic, Inc.'s stock ratings illustrate a nuanced position in the medical technology sector. Analysts reflect a cautious optimism, heavily weighing the 'Hold’ status as a safe bet amidst dynamic healthcare markets. Recent stability in recommendations points to a stalemate between risk and opportunity, with a prospective proof of steadiness in company performance. Future observations need to consider both product innovation and market conditions that could reposition Hologic on stronger investor footing.